3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Thyroid Carcinoma, Anaplastic
2
Skin Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid cancer, follicular
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
Cyclophosphamide
8
Rituximab
5
fludarabine
4
Vincristine
4
Prednisone
4
Doxorubicin
4
fludarabine phosphate
3
Tacrolimus
3
Mycophenolic Acid
3
Etoposide
3
Busulfan
3
venetoclax
2
entrectinib
2
atezolizumab
2
alectinib
2
acalabrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bortezomib
2
trametinib
1
pertuzumab
1
pembrolizumab
1
obinutuzumab
1
liposomal doxorubicin
1
isatuximab
1
ibrutinib
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Vemurafenib
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled